AgenT-797 (MiNK Therapeutics), an allogeneic off-the-shelf invariant natural killer T-cell therapy was well-tolerated and improved survival inpatients with COVID-19-associated acute respiratory distress syndrome (ARDS) in addition to mechanical ventilation or ECMO.
The allogeneic off-the-shelf invariant natural killer T-cell (iNKT) therapy, agenT-797 (MiNK Therapeutics), was well-tolerated and improved survival in patients with COVID-19-associated acute respiratory distress syndrome (ARDS) in addition to mechanical ventilation or ECMO.
The massive tailwinds that fed the sails of hundreds of biotechs during the first 18 months of the Covid-19 pandemic ended up stalling around the beginning of 2022, causing dozens of public and private drug developers alike to enact layoffs, prune their pipelines, shutter and search for alternatives.
Many people would say they know what a diverse company is. Many could recite all the ways a company might encourage or increase diversity in its ranks. Many would recognize a diverse company if they saw one. But few people actually work in one.
CGTLive spoke with Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, to learn more about the advantages of iNKT cells and the company’s CARDIS platform. She discussed data seen so far with AgenT-797.